PUBLIC COMPANY
save$REPLReplimune Group, Inc.
$REPLWoburn, MA, USupdated 18d ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Insider activity
source: SEC Form 4open-market buys + sells
- Apr 2, 26SELLSarchi Christopher· Chief Commercial Officer−$52K↗
routine RSU / option mechanics (6)
- Apr 1, 26grantBAKER BROS. ADVISORS LP · 10% owner44,500 sh
- Apr 1, 26grantBAKER BROS. ADVISORS LP · 10% owner44,500 sh
- Apr 1, 26grantSarchi Christopher · Chief Commercial Officer50,000 sh
- Apr 1, 26grantSarchi Christopher · Chief Commercial Officer75,000 sh
- Apr 1, 26grantAstley-Sparke Philip · 50,000 sh
- Apr 1, 26grantAstley-Sparke Philip · 75,000 sh
🐶 Hiring Signal
News
- Replimune to ride wave of physician support to launch advanced melanoma therapyAnalysts expect Replimune’s newly approved Tudriqev to reach $1.3 billion in peak sales in 2035.biospace · 10d ago
- UniQure welcomes possible adcomm for Huntington’s asset as regulatory ‘jitters’ spread through biopharmaUniQure is ready to put its Huntington’s disease gene therapy through an advisory committee meeting—even as the broader rare disease space has been put on edge by recent FDA scrutiny of assets by R…biospace · 17d ago
Data sources
last refreshed 9m ago
Found something off?
comments(0)
5-min edit window · permanent after that